Adicet Bio Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Chen Schor and Nick Harvey, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Chen Schor | ||
| Chen Schor | President, Chief Executive Officer and Director (principal executive officer) | March 19, 2024 |
| /s/ Nick Harvey | ||
| Nick Harvey | Chief Financial Officer (principal financial officer and principal accounting officer) | March 19, 2024 |
| /s/ Jeffrey Chodakewitz | ||
| Jeffrey Chodakewitz, M.D. | Director | March 19, 2024 |
| /s/ Steve Dubin | ||
| Steve Dubin | Director | March 19, 2024 |
| /s/ Carl L. Gordon | ||
| Carl L. Gordon, Ph.D. | Director | March 19, 2024 |
| /s/ Aya Jakobovits | ||
| Aya Jakobovits, Ph.D. | Director | March 19, 2024 |
| /s/ Michael Kauffman | ||
| Michael Kauffman, M.D., Ph.D | Director | March 19, 2024 |
| /s/ Katie Peng | ||
| Katie Peng | Director | March 19, 2024 |
| /s/ Andrew Sinclair | ||
| Andrew Sinclair, Ph.D. | Director | March 19, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.